论文部分内容阅读
目的:探讨高压氧联合阿替普酶及依达拉奉应用于急性脑梗死临床治疗中的效果。方法:选取惠州市博罗县人民医院2015年1月至2017年1月收治急性脑梗死患者102例,随机分为研究组和对照组。对照组51例,予以阿替普酶、依达拉奉联合治疗;研究组51例,加用高压氧治疗。比较两组患者治疗前后卒中量表评分(NIHSS)改善情况及临床疗效。结果:治疗前,两组美国国立卫生研究院NIHSS评分比较,差异均无统计学意义(P>0.05);治疗后,两组NIHSS评分均有显著改善,差异具有统计学意义(P<0.05),其中研究组NIHSS评分减少程度明显大于对照组,差异具有统计学意义(P<0.05)。研究组加用高压氧治疗后,临床有效率为94.12%,显著优于对照组78.43%,差异具有统计学意义(P<0.05)。结论:高压氧联合阿替普酶及依达拉奉应用于急性脑梗死临床治疗中,可有效改善患者神经功能缺损,提升临床表现,改善预后质量。
Objective: To investigate the effect of hyperbaric oxygen combined with alteplase and edaravone in the clinical treatment of acute cerebral infarction. Methods: A total of 102 patients with acute cerebral infarction who were admitted to Huoluo Boluo People’s Hospital from January 2015 to January 2017 were randomly divided into study group and control group. In the control group, 51 cases were treated with alteplase and edaravone. The study group consisted of 51 cases treated with hyperbaric oxygen. The improvement of stroke score (NIHSS) before and after treatment and the clinical effect were compared between the two groups. Results: Before treatment, there was no significant difference in the NIHSS scores between the two groups (P> 0.05). After treatment, NIHSS scores of both groups were significantly improved (P <0.05) , In which the NIHSS score of the study group decreased significantly more than that of the control group, the difference was statistically significant (P <0.05). The study group with hyperbaric oxygen therapy, the clinical effective rate was 94.12%, significantly better than the control group 78.43%, the difference was statistically significant (P <0.05). Conclusion: Hyperbaric oxygen combined with alteplase and edaravone can be used in clinical treatment of acute cerebral infarction, which can effectively improve neurological deficit, improve clinical manifestations and improve prognosis quality.